Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.

In the present study, CSF concentrations of NFL, t-tau, p-tau, GFAP, S-100B, YKL-40, MCP-1, α-sAPP, β-sAPP, and Aβ38, Aβ40, Aβ42 were measured in 324 MS patients to test whether a correlation among the biomarkers exists and whether the profile of CSF biomarkers varies among the different types of MS. The CSF concentrations of NFL were significantly higher in RRMS while CSF concentrations of GFAP were higher in PPMS. CSF concentrations of NFL correlated with YKL-40 in CIS patients while CSF concentrations of GFAP correlated with YKL-40 in RRMS patients.

• Publication year

  2016

• Venue

  Journal of Neuroimmunology

• Publication date

  2016-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jneuroim.2016.08.004PMID 27725108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

  2015cited by this paper
• Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

  2015cited by this paper
• Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke

  2014cited by this paper
• Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling.

  2013cited by this paper
• A comparative study of CSF neurofilament light and heavy chain protein in MS

  2013cited by this paper
• Multiplexing and multivariate analysis in neurodegeneration.

  2012cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

  2010cited by this paper
• Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

  2010cited by this paper
• In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases

  2010influential reference
• The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.

  2010cited by this paper
• The relation between inflammation and neurodegeneration in multiple sclerosis brains

  2009cited by this paper
• Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

  2009cited by this paper
• Multiple sclerosis diagnostic criteria: three years later

  2005cited by this paper
• Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype

  2003cited by this paper
• Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

  2003cited by this paper
• S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions.

  1999cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998influential reference
• Axonal damage in acute multiple sclerosis lesions.

  1997cited by this paper
• Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

  1997cited by this paper
• Amyloid precursor protein (APP) expression in multiple sclerosis lesions

  1995cited by this paper
• GFAP and Astrogliosis

  1994influential reference
• EDMUS, a European database for multiple sclerosis.

  1992cited by this paper
• The distribution of tau in the mammalian central nervous system

  1985cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper

• Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis

  2026cites this paper
• Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis

  2025cites this paper
• Effects of Physical Exercise on Neurofilament Light Chain and Glial Fibrillary Acidic Protein Level in Patients with Multiple Sclerosis: A Systematic Review and Bayesian Network Meta-Analysis

  2025cites this paper
• Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis

  2025cites this paper
• Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).

  2025cites this paper
• Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS

  2025cites this paper
• Biomarkers of progressive multiple sclerosis decrease following autologous hematopoietic stem cell transplantation

  2025cites this paper
• Biomarkers Differentiating RRMS and SPMS in Multiple Sclerosis—A Systematic Review

  2024influential citation
• CHI3L1 in Multiple Sclerosis—From Bench to Clinic

  2024influential citation
• Serum Vitamin D3 as a Potential Biomarker for Neuronal Damage in Smoldering Multiple Sclerosis

  2024cites this paper
• Can Selected Parameters of Brain Injury Reflect Neuronal Damage in Smoldering Multiple Sclerosis?

  2024cites this paper
• A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis

  2024cites this paper
• Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis

  2023cites this paper
• Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing–remitting multiple sclerosis: a 20-year follow-up cohort

  2023cites this paper
• Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammation

  2023cites this paper
• Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.

  2023cites this paper
• The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?

  2023cites this paper
• Biochemical biomarkers for multiple sclerosis.

  2023cites this paper
• Development of an ultrasensitive microfluidic assay for the analysis of Glial fibrillary acidic protein (GFAP) in blood

  2023cites this paper
• Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

  2023cites this paper
• Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis

  2022cites this paper
• Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

  2022cites this paper
• An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis

  2022cites this paper
• Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis

  2022cites this paper
• Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

  2022cites this paper
• [Herpesviruses and biomarkers in disseminated encephalomyelitis and multiple sclerosis in children (part II)].

  2021cites this paper
• Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis

  2021influential citation
• Potential Role of CHI3L1+ Astrocytes in Progression in MS

  2021cites this paper
• Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.

  2021cites this paper
• A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis.

  2021cites this paper
• Linking immune-mediated damage to neurodegeneration in multiple sclerosis: could network-based MRI help?

  2021cites this paper
• Validation of the BESTest for Measuring Balance in People With Multiple Sclerosis

  2021influential citation
• A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course

  2020cites this paper
• Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis

  2020influential citation
• Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

  2020cites this paper
• Neurofilaments in progressive multiple sclerosis: a systematic review

  2020cites this paper
• YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation

  2020cites this paper
• Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS

  2020cites this paper
• Serum Glial Fibrillary Acidic Protein: A Surrogate Marker of the Activity of Multiple Sclerosis

  2020cites this paper
• Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease

  2019cites this paper
• Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

  2019cites this paper
• Astrocytes in myelination and remyelination.

  2019cites this paper
• Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis

  2019cites this paper
• Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection

  2019cites this paper
• Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

  2019cites this paper
• Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer’s Disease Pathology

  2019cites this paper
• CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration

  2018cites this paper
• Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study

  2018cites this paper
• Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study

  2018cites this paper
• Cerebrospinal fluid GAP-43 in early multiple sclerosis

  2018cites this paper
• THE ROLE OF CELLULAR AND EXOSOMAL NEURAL-DERIVED LONG NON CODING RNA (LNCRNA) IN MULTIPLE SCLEROSIS: POTENTIAL BIOMARKERS OF DISEASE SUSCEPTIBILITY AND PROGRESSION

  2018cites this paper
• YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression

  2018cites this paper
• Serum GFAP as a biomarker for disease severity in multiple sclerosis

  2018cites this paper
• Fluid biomarker and electrophysiological outcome measures for progressive MS trials

  2017cites this paper
• Longitudinal Cerebrospinal Fluid Biomarkers of Alzheimer Disease: Movement Toward the Diagnosis, Prognosis and Staging of Disease

  2017cites this paper
• GFAP in early multiple sclerosis: A biomarker for inflammation.

  2017cites this paper
• Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges.

  2017cites this paper
• Multiple sclerosis: Biomarkers and genetic variants reflect disease course in multiple sclerosis

  2016cites this paper
• Brain parenchymal fraction in healthy individuals and in clinical follow-up of multiple sclerosis

  2016cites this paper
• Role of Chitinase 3 – like 1 as a Biomarker in Multiple Sclerosis A Systematic Review and Meta-analysis

  year unknowncites this paper